معرفی
David Tétard is a Research Fellow in the Department of Chemistry at the University of Northumbria at Newcastle. His research focuses on designing novel metal chelators, particularly targeting Fe(III), for therapeutic applications in cancer, neurodegenerative diseases, and antimicrobial agents. He leads projects on anticancer drug development, neuroprotection in Parkinson's and Alzheimer's diseases, and biostatic mechanisms. Dr. Tétard currently supervises PhD student Darren Gardner on siderophore-chromogen conjugates for pathogen detection. His work integrates organic synthesis, pharmacology, and cell biology, with 10+ peer-reviewed publications since 2017. Education includes a Chemistry PhD (1996) and Fellowships with the Higher Education Academy (2013) and Royal Society of Chemistry (1998).
- Key Research Themes: Metal chelation therapy, drug design, neurodegenerative disease modeling, anticancer agents.
- Recent Projects: Development of SK4 iron chelator for ovarian cancer therapy, neuroprotective pyridinone derivatives for Parkinson's disease.
Publications emphasize multidisciplinary approaches, combining synthetic chemistry with in vitro cellular models to validate therapeutic efficacy. Current research trends highlight dual-action chelators with both metal-binding and enzyme-inhibitory properties. No awards explicitly listed, though active grant-funded projects are implied through publication output. Supervision includes one registered PhD student with focus on diagnostic applications of chelators.
